ArticleScientific reports2026
KIF20A promotes cervical cancer progression by interacting with CLIP1.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cervical cancer (CC) remains a major cause of cancer-related mortality among women worldwide. Although screening and vaccination have reduced its incidence, advanced-stage cases still pose a serious clinical challenge. This study aimed to identify novel biomarkers and therapeutic targets for CC through integrated bioinformatics and experimental approaches. Analysis of multiple datasets (GSE63514, GSE67522, and TCGA-GTEx) revealed 426 consistently upregulated genes in CC, among which several kinesin family members, including kinesin family member 20 A (KIF20A), were significantly overexpressed. KIF20A mRNA and protein levels were markedly elevated in CC patient tissues (n = 306 tumors vs. 22 normal controls). Functional assays demonstrated that KIF20A knockdown strongly inhibited cell proliferation, migration, and tumor growth in vitro and in vivo. Mechanistically, KIF20A interacts with CAP Gly domain containing linker protein 1 (CLIP1) and enhances its protein stability. Rescue experiments confirmed that CLIP1 silencing reversed the oncogenic effects of KIF20A overexpression. These results unveil a previously unrecognized KIF20A-CLIP1 regulatory axis in CC progression and suggest its potential as both a biomarker and a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.